Heighten Science Publications Inc.

Tag: #aHUS

  • Plasma Therapy in aHUS Patient with SARS-CoV-2 Infection

    Plasma Therapy in aHUS Patient with SARS-CoV-2 Infection

    —

    by

    Vishnu
    in

    Introduction Atypical Hemolytic Uremic Syndrome (aHUS) is a rare condition characterized by complement-mediated thrombotic microangiopathy. Patients with aHUS who contract SARS-CoV-2 face a heightened risk of disease recurrence due to complement system activation. However, the management of such cases remains an area of ongoing research. This article explores a recent case study where convalescent plasma…

  • Eculizumab Failure and the Off-Label Use of Ravulizumab

    Eculizumab Failure and the Off-Label Use of Ravulizumab

    —

    by

    Vishnu
    in

    Introduction Atypical Hemolytic Uremic Syndrome (aHUS) is a rare and severe disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. This case report highlights a catastrophic form of aHUS that was unresponsive to Eculizumab and required the off-label use of Ravulizumab, leading to successful hematologic recovery but progression to end-stage kidney disease. For more…

  • Plasma Therapy in aHUS Patient with SARS CoV Infection from Journal of Clinical Nephrology

    Plasma Therapy in aHUS Patient with SARS CoV Infection from Journal of Clinical Nephrology

    —

    by

    Vishnu
    in

    Introduction Atypical Hemolytic Uremic Syndrome (aHUS) is a rare but severe condition that affects the complement system, leading to thrombotic microangiopathy and potential organ damage. Given the complexities of managing aHUS during a SARS-CoV-2 infection, this case study explores the successful use of convalescent plasma therapy in a patient with aHUS and COVID-19. Visit HSPIOA…